Feb 26 2025 Feedback. |
[ Consensus Pharmacophore | Pairwise APF Score | APF Ligand Based Screen | 3D QSAR ]
The Atomic Property Fields (APF) superposition/alignment method was first reported by Maxim Totrov PhD (Principal Scientist - MolSoft) at the 2007 233rd American Chemical Society National Meeting, Chicago, IL USA and then published here. This section shows you how to:
To generate a Consensus Pharmacophore based on APF fields use the Chemistry/APF Tools/Consensus Ph4 menu option. First convert your chemical into an ICM object.
To determine how well the APF fields of two chemicals match you can determine the Pairwise APF Score using the Chemistry/APF Tools/Pairwise APF Score menu option.
This option allows you to perform a ligand-based screen using the Atomic Property Fields of superimposed chemicals. SD files are screened and the ligands are scored according to their fit into the APF field. The documentation for this option is in the Screening Chapter.
| Tutorial| This 3D QSAR approach uses MolSoft's Atomic Property Fields 3D pharmacophores as described in this paper.
APF 3D QSARAtomic Property Field (APF) 3D QSAR is a method for predicting the biological activity of molecules based on their spatial atomic properties. Unlike traditional QSAR approaches, APF captures the 3D distribution of molecular features to improve prediction accuracy. Modeling Molecular ActivityThe contribution of different molecular fragments to the APF model is weighted, allowing for a quantitative prediction of new molecules. This is expressed mathematically in Equation 3. By incorporating specific weight factors, the model refines activity predictions beyond a simple additive approach, ensuring that the molecular properties are accurately represented in a biologically relevant context. These weight factors are optimized based on experimental data, leading to a more precise predictive model. Linking to Binding EnergyTo predict the binding energy (ΔG), the APF pseudo-energy is used to approximate the actual binding energy, as shown in Equation 4. This approach allows for a rapid assessment of molecular interactions by correlating APF-derived energy values with experimentally determined binding affinities. The pseudo-energy calculation considers molecular shape, electrostatic properties, and steric effects, ensuring a comprehensive representation of binding potential. Summary of APF 3D QSARIn the superposition and virtual ligand screening (VLS) procedures, the original APF model assigned equal weights to all ligands in the training set. However, to enable quantitative activity prediction, individual weight factors (xki) are introduced for each compound and APF component. These weights are optimized using training set activity data to better reproduce experimental results (see Equation 3). To estimate a compound's binding energy, the APF pseudo-energy is calculated, assuming it approximates the actual binding energy (see Equation 4). By substituting the APF model into this equation, the summation order is rearranged to introduce partial APF energy components (Ekli), which simplify the calculation (see Equation 5). The optimal weights (xki) are determined using a partial least squares (PLS) regression approach, where a matrix of pre-calculated APF potentials is used. The leave-one-out cross-validation technique ensures the selection of the best number of latent variables. Once derived, these weights are applied to combine per-compound potentials into a single weighted APF QSAR model, allowing for rapid activity prediction of new compounds through a single pseudo-energy calculation. There are three steps to undertake APF 3D QSAR:Step 1: Chemical Superposition
Step 2: Learning
Step 3: Prediction
After running the model there are some additional visualization options located in the tabs in Chemistry/APF Tools/APF 3D QSAR/.
|
Copyright© 1989-2025, Molsoft,LLC - All Rights Reserved. |
This document contains proprietary and confidential information of
Molsoft, LLC. The content of this document may not be disclosed to third parties, copied or duplicated in any form, in whole or in part, without the prior written permission from Molsoft, LLC. |